Hympavzi (marstacimab-hncq) — Medica

Hemophilia B without Factor IX inhibitors

Initial criteria

age ≥ 12 years
using Hympavzi for routine prophylaxis to prevent or reduce the frequency of bleeding episodes
has moderately severe to severe hemophilia B as evidenced by baseline Factor IX level ≤ 2% (without Factor IX replacement therapy)
EITHER (a) Factor IX inhibitor titer testing performed within the past 30 days AND inhibitor titer < 1.0 Bethesda units/mL OR (b) has not received Factor IX therapy in the past
prophylactic use of Factor IX products will be discontinued (use for breakthrough bleeding allowed)
prescribed by or in consultation with a hemophilia specialist

using Hympavzi for routine prophylaxis to prevent or reduce the frequency of bleeding episodes
prophylactic use of Factor IX products will not occur while receiving Hympavzi (use for breakthrough bleeding allowed)
prescribed by or in consultation with a hemophilia specialist
patient experienced a beneficial response to therapy (e.g., reduction in bleeding events, severity, or spontaneous bleeds)

1 year